Jernkarboksymaltose

Ferric carboxymaltose, the active ingredient in Jernkarboksymaltose, is an intravenous iron supplement presented as an injection solution for intravenous use. It treats iron deficiency anemia and related conditions in adults, including anemia due to chronic kidney disease, postoperative or postpartum states, and patients who cannot tolerate oral iron.

GNH USA supplies Jernkarboksymaltose as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies, clinics and other healthcare facilities worldwide.

Jernkarboksymaltose is used to correct iron deficiency and related anemia conditions. - Iron deficiency anemia: restores hemoglobin levels and replenishes iron stores in patients with documented deficiency. - Anemia due to chronic kidney disease: provides rapid iron repletion to support erythropoiesis in CKD patients. - Post‑operative or postpartum anemia: corrects acute blood loss‑related anemia after surgery or childbirth. - Intolerance to oral iron: offers an effective alternative for patients who experience gastrointestinal side effects from oral preparations.

Jernkarboksymaltose may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate upset stomach after infusion. - Headache: transient headache during or shortly after administration. - Dizziness: occasional light‑headedness, especially with rapid infusion. - Injection site pain: local discomfort or erythema at the infusion site. - Flushing: brief warmth or redness of the skin. - Mild hypotension: temporary drop in blood pressure during infusion.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical intervention. - Severe hypotension: marked blood pressure decline that may need treatment. - Acute respiratory distress: difficulty breathing or bronchospasm. - Serum ferritin overload: excessive iron accumulation leading to organ toxicity. - Hepatic injury: rare liver enzyme elevations. - Hypersensitivity reactions: rash, urticaria, or angioedema.

Before using Jernkarboksymaltose, clinicians should consider several safety measures. - Assess iron status before administration: confirm deficiency with ferritin and transferrin saturation measurements. - Monitor for hypersensitivity: observe the patient during and after infusion for allergic signs. - Avoid rapid infusion rates: follow recommended infusion guidelines to reduce cardiovascular events. - Use with caution in patients with active infection or inflammation: iron may exacerbate microbial growth. - Do not mix with calcium‑containing solutions: incompatibility can cause precipitation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Jernkarboksymaltose can interact with other medicines; some require avoidance while others need monitoring.

Major Interactions (Avoid): - Concurrent use of other intravenous iron products: risk of iron overload. - Concurrent use of erythropoiesis‑stimulating agents without monitoring: may cause excessive hemoglobin rise. - Concurrent use of high‑dose intravenous vitamin C: enhances iron absorption leading to toxicity.

Moderate Interactions (Monitor Closely): - Oral iron supplements: may affect laboratory iron measurements; separate dosing times. - Chelating agents (e.g., deferoxamine): can reduce the efficacy of administered iron. - Antihypertensive drugs: monitor blood pressure due to possible hypotensive effects during infusion.